- Open Access
Erratum to: Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial
Retrovirologyvolume 13, Article number: 35 (2016)
The original article was published in Retrovirology 2016 13:21
Erratum to: Retrovirology (2016) 13:21 DOI 10.1186/s12977-016-0251-3
The original version of this article unfortunately contained a mistake. The “Acknowledgement” section was incorrect and included Dr. Catherine Tamalet. Dr. Catherine Tamalet should not be included in the “Acknowledgement” section for the following reasons:
Dr. Catherine Tamalet requests to be withdrawn from the “Acknowledgements” section in this article, on the following grounds: (a) No permission was asked of her to be acknowledged. (b) She did not read the manuscript before its publication. (c) The method depicted in the “Methods” section to quantify HIV DNA [“Generic HIV assay (Biocentric, Bandol, Provence) with a cut off of 20 copies/million of peripheral blood mononuclear cells (PBMC)”] is not the method employed in her laboratory. Dr. Tamaret routinely employs an “in-House” method with a cut-off of 20 copies. Dr. Thamalet was in the acknowledgement for fruitful discussion and not for her participation to the study.
Dr. Catherine Tamalet has been removed from the original article .
Loret EP, et al. Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial. Retrovirology. 2016;13:21. doi:10.1186/s12977-016-0251-3.
The online version of the original article can be found under doi:10.1186/s12977-016-0251-3.